Literature DB >> 34003350

Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.

Koung Mi Kang1,2, Seung Hong Choi3,4,5, Park Chul-Kee6, Tae Min Kim7, Sung-Hye Park8, Joo Ho Lee9, Soon-Tae Lee10, Inpyeong Hwang1,2, Roh-Eul Yoo1,2, Tae Jin Yun1,2, Ji-Hoon Kim1,2, Chul-Ho Sohn1,2.   

Abstract

OBJECTIVE: This study aimed to evaluate whether arterial input functions (AIFs) obtained from dynamic susceptibility contrast (DSC)-MRI (AIFDSC) improve the reliability and diagnostic accuracy of dynamic contrast-enhanced (DCE)-derived pharmacokinetic (PK) parameters for differentiating glioblastoma from primary CNS lymphoma (PCNSL) compared with AIFs derived from DCE-MRI (AIFDCE).
METHODS: This retrospective study included 172 patients with glioblastoma (n = 147) and PCNSL (n = 25). All patients had undergone preoperative DSC- and DCE-MRI. The volume transfer constant (Ktrans), volume of the vascular plasma space (vp), and volume of the extravascular extracellular space (ve) were acquired using AIFDSC and AIFDCE. The relative cerebral blood volume (rCBV) was obtained from DSC-MRI. Intraclass correlation coefficients (ICC) and ROC curves were used to assess the reliability and diagnostic accuracy of individual parameters.
RESULTS: The mean Ktrans, vp, and ve values revealed better ICCs with AIFDSC than with AIFDCE (Ktrans, 0.911 vs 0.355; vp, 0.766 vs 0.503; ve, 0.758 vs 0.657, respectively). For differentiating all glioblastomas from PCNSL, the mean rCBV (AUC = 0.856) was more accurate than the AIFDSC-driven mean Ktrans, which had the largest AUC (0.711) among the DCE-derived parameters (p = 0.02). However, for glioblastomas with low rCBV (≤ 75th percentile of PCNSL; n = 30), the AIFDSC-driven mean Ktrans and vp were more accurate than rCBV (AUC: Ktrans, 0.807 vs rCBV, 0.515, p = 0.004; vp, 0.715 vs rCBV, p = 0.045).
CONCLUSION: DCE-derived PK parameters using the AIFDSC showed improved reliability and diagnostic accuracy for differentiating glioblastoma with low rCBV from PCNSL. KEY POINTS: • An accurate differential diagnosis of glioblastoma and PCNSL is crucial because of different therapeutic strategies. • In contrast to the rCBV from DSC-MRI, another perfusion imaging technique, the DCE parameters for the differential diagnosis have been limited because of the low reliability of AIFs from DCE-MRI. • When we analyzed DCE-MRI data using AIFs from DSC-MRI (AIFDSC), AIFDSC-driven DCE parameters showed improved reliability and better diagnostic accuracy than rCBV for differentiating glioblastoma with low rCBV from PCNSL.

Entities:  

Keywords:  Diagnostic imaging; Glioblastoma; Lymphoma; Magnetic resonance imaging; Perfusion imaging

Year:  2021        PMID: 34003350     DOI: 10.1007/s00330-021-08044-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  41 in total

1.  Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging.

Authors:  Marius Hartmann; Sabine Heiland; Inga Harting; Volker M Tronnier; Clemens Sommer; Roman Ludwig; Klaus Sartor
Journal:  Neurosci Lett       Date:  2003-02-27       Impact factor: 3.046

2.  Primary CNS lymphoma.

Authors:  Uwe Schlegel
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 3.  Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.

Authors:  G Thompson; S J Mills; D J Coope; J P B O'Connor; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

4.  The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death.

Authors:  P P Molnár; B P O'Neill; B W Scheithauer; D R Groothuis
Journal:  Neuro Oncol       Date:  1999-04       Impact factor: 12.300

Review 5.  Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.

Authors:  I S Haldorsen; A Espeland; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

Review 6.  Primary central nervous system lymphoma: radiologic-pathologic correlation.

Authors:  K K Koeller; J G Smirniotopoulos; R V Jones
Journal:  Radiographics       Date:  1997 Nov-Dec       Impact factor: 5.333

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience.

Authors:  Riyadh N Al-Okaili; Jaroslaw Krejza; John H Woo; Ronald L Wolf; Donald M O'Rourke; Kevin D Judy; Harish Poptani; Elias R Melhem
Journal:  Radiology       Date:  2007-05       Impact factor: 11.105

9.  Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation.

Authors:  P Kickingereder; F Sahm; B Wiestler; M Roethke; S Heiland; H-P Schlemmer; W Wick; A von Deimling; M Bendszus; A Radbruch
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-10       Impact factor: 3.825

10.  Analysis of perfusion weighted image of CNS lymphoma.

Authors:  In Ho Lee; Sung Tae Kim; Hyung-Jin Kim; Keon Ha Kim; Pyoung Jeon; Hong Sik Byun
Journal:  Eur J Radiol       Date:  2009-06-04       Impact factor: 3.528

View more
  2 in total

Review 1.  Construction and imaging of a neurovascular unit model.

Authors:  Taiwei Dong; Min Li; Feng Gao; Peifeng Wei; Jian Wang
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

2.  CNS Lymphoma: Clinical Pearls and Management Considerations.

Authors:  Michelot Michel; Noelle Lucke-Wold; Mohammad Reza Hosseini; Eric Panther; Ramya Reddy; Brandon Lucke-Wold
Journal:  Biomed Res Clin Rev       Date:  2022-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.